The massive overhang of 24.9M registered shares (18.6x current float) creates significant selling pressure risk, especially given the large discount between the PIPE price (~$13.85) and current market price ($31.79). Monitor for stockholder vote on authorized share increase and Nasdaq approval, which would trigger conversion and enable selling. Expect volatility as selling stockholders may look to lock in gains.
Price Chart
Executive Summary
Sensei Biotherapeutics filed an S-3 registration statement to register up to 24,868,028 shares of common stock for resale by selling stockholders, consisting of shares issuable upon conversion of Series B Preferred Stock issued in connection with the acquisition of Faeth Therapeutics and a concurrent $200M private placement. The company will not receive any proceeds from the resale of these shares, but the registration enables existing investors to sell their positions, creating potential overhang on the stock.
Key Facts
- S-3 registers 24,868,028 shares for resale by selling stockholders, representing ~18.6x the current 1,340,333 shares outstanding as of March 31, 2026.
- Shares consist of 10,425,531 Merger Conversion Shares, 14,440,395 Private Placement Conversion Shares, and 2,102 Warrant Conversion Shares.
- Concurrent $200M private placement priced at ~$13.85 per share (as-converted basis), closed February 20, 2026.
- Conversion of Series B Preferred Stock requires stockholder approval to increase authorized shares from 12.5M to 300M and Nasdaq approval.
- Company will not receive proceeds from resale; only potential proceeds from cash exercise of the warrant.
- Lock-up agreements of 180 days apply to certain stockholders, but many selling stockholders are not subject to lock-up.
- Stock closed at $31.79 on April 24, 2026, significantly above the ~$13.85 PIPE price.
Financial Impact
Potential dilution of up to 1,855% relative to current shares outstanding; $775M aggregate market value of registered shares at recent price.
Risk Factors
- Massive dilution overhang could depress share price as selling stockholders monetize positions.
- Stockholder vote required for conversion may fail, delaying but not eliminating overhang.
- Nasdaq listing application approval is uncertain and could delay conversion.
- Beneficial ownership limitations (4.99%-19.99%) may slow but not prevent selling.
- Company is a clinical-stage biotech with no approved products; fundamental risk remains high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-183535 |
| Document: d133316dexfilingfees.htm | 0001193125-26-183535 |
| Document: d133316dex51.htm | 0001193125-26-183535 |
| Document: d133316dex231.htm | 0001193125-26-183535 |
| Document: d133316dex232.htm | 0001193125-26-183535 |
| Document: 0001193125-26-183535-index-headers.html | 0001193125-26-183535 |
| Document: 0001193125-26-183535-index.html | 0001193125-26-183535 |
| Document: 0001193125-26-183535.txt | 0001193125-26-183535 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 19w ago | 3 | $13.86 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 8-K | $13.04 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | EFFECT | $13.04 | awaiting T+5 | — | — |
Jun 10, 2026 19w ago | S-3/A | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 10, 2026 19w ago | 8-K | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 2, 2026 21w ago | 10-K/A | $16.10 $12.63 | ▼ −21.53% | ▼ −18.56% | — |
Jun 2, 2026 21w ago | S-3/A | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
Jun 1, 2026 21w ago | Insider Cluster | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
May 22, 2026 22w ago | DEFA14A | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
May 22, 2026 22w ago | 8-K | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers